We continue to hold CWN.ASX with a view the stock can trade up to our $14 target in the coming months.
FY17 revenue of $3.8b, EBIT forecast of $700m, ESP of $0.67 paying out around $0.55 in dividends, places the stock on a 4.4% forward yield.
Continue to hold.
ORG.ASX released the June quarter production numbers that were slightly better than market expectations.
This supports our gradual recovery outlook for ORG and we see FY 17 revenue of $12b producing an EBIT of $1.1b on reported profit in the range of $700m.
Dividend is likely to remain unchanged at $0.20 which puts the stock on a 3.5% forward yield.
RMD.ASX traded at our $9.00 profit target today. The stock has put on 20% since our buy trigger. Patience has paid off here and waiting for todays earnings result has proven to be the right approach.
ResMed’s annual profit for the year to June 30 was $US352m on annual revenue of $US1.8b, up from $US1.7b. Revenue for the fourth quarter lifted 15 per cent to $US519m boosted by the acquisition in healthcare software group Brightree. Quarterly dividend raised to 33 US cents per share.
Our algorithm engines will continue to track RMD.ASX for future buying opportunities and I’ll be sure to keep you informed.
Enjoy the proceeds of this quick profit!
QUB.ASX has today traded at our $2.50 profit target. Bank the 12%+ profit on this investment.
Our algorithm engines will continue monitoring QUB.ASX and I’ll be sure to alert you, when the next buying signal occurs.
FMG.ASX has rallied from $1.50 to $4.50 in the past 6 months. June Quarter shipments were strong and the company continues with further cost reduction. US$600m reduction in net debt and positive FY17 guidance of 170 Mt.
AGL.ASX is in our buy write basket. Buy at $20.00 and sell the $20.50 Nov call options for $0.60 and collect the $0.35 August dividend. $0.95 cash flow for 4 months or $2.85 annualised = 14% annualised cash low return.
Analysts are a little too bullish on the outlook for AGL but I think downside risks are minimal and we should see EPS grow by 5% and DPS of $0.70 in FY17 and $0.73 in FY18. NPAT FY17 of 905m and growing to FY18 of $950m.
This allocation is for income seekers and not traders.
RMD.ASX 4Q16 results come out tomorrow. Will be interesting to see the numbers, we hold this name in the model portfolio and we’re looking for ongoing strength through to our $9.00 exit target.
Looking for NPAT of around $370 – 380million and 29 cents of dividends. Watching the sales growth rate data on the US flow generators.
Qube Holding Ltd (QUB.ASX) is starting to trend higher as expected. The premise of this trade is the market will begin to re-rate QUB following the finalisation of the asset purchases from Asciano. Traders may look to take take profit around the $2.50 level.
Keep this one on your radar as the 2 to 3 year outlook should see this stock present multiple buying opportunities. Our algorithm engines will continue tracking for optimum entry and exit levels.
Short BEN.ASX (update)
Following the short recommendation on the 1st of June and our $9.10 target, it’s worth highlighting that Bendigo Bank hit our target (traded down to $8.91) two weeks later and a profit of over 10% in less than 10 trading days. Bendigo has now bounced and traded back up towards a sell price that puts the short trade back on our radar again, however, until the broader market indices rollover, we’re not focused on new short positions just yet.
Stay tuned.
Long AMC.ASX (update)
Amcor is now trading $15.75 or +10% from our buy range indicated in June. The nimble or leveraged trader should consider taking profit now, the investor may prefer to sell the $16.00 November call options for 50 -60 cent credit and keep exposure to the upcoming September dividend of approximately 28 cents.
Level 17 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453